Neurokinin antagonists and uses thereof
AssigneeCalifornia Institute of Technology
InventorsDavid J. Anderson, Moriel Zelikowsky, Andrea Choe
Life of this patent
Estimating the term…
Abstract
In some embodiments, methods of inhibiting, ameliorating, reducing the severity of, treating, reducing the likelihood of, or preventing social isolation stress or symptoms thereof in a subject in need thereof are described. In some embodiments, methods of determining a risk of social isolation stress in a subject are described.
Claims23
A method of inhibiting, ameliorating, reducing the severity of, or treating one or more symptoms caused by social isolation stress, the method comprising:
- identifying a subject as suffering from social isolation stress and in need of inhibiting, ameliorating, reducing the severity of, or treating one or more symptoms caused by the social isolation stress, wherein the subject does not have Alzheimer's disease or schizophrenia;
- and
- administering an effective amount of a neurokinin receptor antagonist to the subject, wherein the neurokinin receptor antagonist is a NK3R antagonist, to thereby inhibit, ameliorate, reduce the severity of, or treat the one or more symptoms caused by the social isolation stress.
A method of treating a subject for one or more symptoms caused by social isolation stress, comprising:
- identifying a subject as suffering from social isolation stress, wherein the subject does not have Alzheimer's disease or schizophrenia;
- and
- administering an effective amount of a neurokinin receptor antagonist to the subject, to thereby treat one or more symptoms caused by social isolation stress,
- wherein the neurokinin receptor antagonist is a NK3R antagonist, and
- wherein the subject, before administering the neurokinin receptor antagonist, has an elevated level of neurokinin B induced by deprivation of social interaction or contact.
Dependencies are inferred from the claim text.